Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Investor Presentation (May 2023)
20 slides from Anatara Lifesciences's investor presentation, May 8, 2023
Slide 1: Anatara Lifesciences Ltd Investor Presentation
Anatara Lifesciences Ltd Investor Presentation For personal use only May 2023 ASX: ANR
Slide 2: Disclaimer
For personal use only Disclaimer The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN
Slide 3: Specialising in the Gastrointestinal Tract
Specialising in the Gastrointestinal Tract Evidenced-based solutions for gastrointestinal tract health issues About Anatara Investment Highlights For personal use only Anatara Lifesciences Ltd (ASX:ANR) is focused on the Novel Technology validation and commercialisation of innovative, evidence- ▪ Ga
Slide 4: Gut Health promotes general wellbeing
For personal use only Gut Health promotes general wellbeing Gut Brain Axis & Mental Health Wellbeing & weight management The gut and the brain communicate with each other Gut health influences a range of weight through a complex network of nerves, hormones, and management-related body functions chem
Slide 5: Key Management & Board of Directors
Key Management & Board of Directors Highly experienced Board & Management For personal use only Anatara’s nimble Board and Management structure provides significant experience and flexibility for potential corporate transactions. John Michailidis, COO Dr David Brookes, Executive Chair • John is an e
Slide 6: Gastrointestinal Health: GaRP progressing towards commercialisation
Gastrointestinal Health GaRP progressing towards commercialisation Gastrointestinal RePrograming (GaRP) technology for ‘gut health’ For personal use only Active pivotal clinical trial – Irritable Bowel Syndrome ▪ Primary Endpoint – Efficacy of ‘GaRP’ for irritable bowel syndrome ▪ 140* patient, plac
Slide 7: Active Program
Active Program Anatara has multiple active programs approaching commercial outcomes Pre-Clinical Clinical For personal use only Proof of Commercial Program Product Indication Population Delivery Discovery In-Vitro In-Vivo Pivotal Registration Concept Rights Irritable bowel Ages 18- Oral 3Q 4Q Listed
Slide 8: GaRP: One product, multiple benefits
GaRP Bromelain Menthol One product, multiple benefits Reduces pro- Antispasmodic for inflammatory For personal use only cytokines & serotonin; smooth muscle promotes healing via GITract mucin genes Patent Protected - Scientifically designed to manage and control background IBS symptoms as well as ep
Slide 9: Gastrointestinal RePrograming (GaRP): A potential breakthrough for gut health
Gastrointestinal RePrograming (GaRP) A potential breakthrough for gut health For personal use only Unique knowledge of Ingredients are Well-characterised Potential Gut-Brain bromelain’s ‘fingerprint’ GRAS proprietary formula synergistic effects Connection Function within formulation and potential im
Slide 10: GaRP – Grounded in scientific evidence
GaRP – Grounded in scientific evidence GaRP addresses the underlying factors of gastrointestinal disorders For personal use only Diseased Gut GaRP gut repair in action GaRP regenerated gut Leaky ‘tight junctions’ allow pathogens to Increase in mucin gene expression to Restored ‘tight junctions’ allo
Slide 11: Snapshot: IBS and IBD
Snapshot: IBS and IBD Gastrointestinal disorders are highly prevalent and poorly managed For personal use only IBS affects IBD affects 11% >5m of the global population 6 people globally, with accelerating incidence7 Debilitating Symptoms Patients seek alternative options Patients experience symptoms
Slide 12: Market Opportunity
Market Opportunity The gut health market is significant, lacking effective, evidence-based solutions For personal use only Digestive Health Market to be valued at US$23.4B in 2030 $23.4B Growth rate of 8.1% to be sustained by: $21.6B ▪ High prevalence of disease – Obesity, digestive $20.0B disorders
Slide 13: Significant Corporate Interest
Significant Corporate Interest Global Trend of Research & Development In Gastrointestinal Health Several examples of investment and/or collaboration by industry leaders in gastrointestinal health For personal use only Further Company #1 Stock Details Company #2 Stock Details Rationale of Deal Agreem
Slide 14: Corporate/PE/VC Interest
Corporate/PE/VC Interest Significant corporate interest in the wellness and gut health sectors Corporate Interest in the Wellness space For personal use only Acquirer Stock Details Target Stock Details Rationale of Deal Agreement TYO: 2503 Japanese brewer Kirin acquired Australian vitamins maker Bla
Slide 15: Clinical trial – Irritable Bowel Syndrome
Clinical trial – Irritable Bowel Syndrome Robust clinical trial to validate the effectiveness of GaRP Stage 1 Stage 2 110 Patients (randomised, double- For personal use only blind placebo controlled) Cohort 1: 30 Patients on placebo Cohort 1: 55 Patients on Final results readout placebo 90 Patients:
Slide 16: Licensing discussions & portfolio diversification
Licensing discussions & portfolio diversification Progressing licensing discussions with global consumer health companies for GaRP For personal use only Global Partners Local Partners Anatara is experiencing inbound interest from global leaders Partnerships with regional leaders in 'gut' health to l
Slide 17: Pipeline Programs
Pipeline Programs Discussing licencing potential with producers and animal feed/nutrition companies Human Health For personal use only ▪ Extensions for GaRP’s broad indications for use-trial planning IBD paediatrics (synergistic effect of reduce immune suppressant dosing) & pilot Functional Dyspepsi
Slide 18: Advisory Board and DSMB members
Advisory Board and DSMB members Highly accomplished Advisory Board to guide ANR through to commercialisation For personal use only Advisory Board members are internationally recognised for their expertise in IBS and IBD with experience ranging from preclinical drug development through to translation
Slide 19: Contact Anatara Lifesciences Ltd
For personal use only Contact Anatara Lifesciences Ltd David Brookes, Executive Chair +61 0411 712 579 www.anataralifesciences.com @AnataraANR anatara-lifesciences-ltd Investor Relations Dirk van Dissel Candour Advisory E: dirk@candouradvisory.com.au
Slide 20: Glossary
Glossary IBS Irritable bowel syndrome (IBS) is a condition that affects the colon (also referred to as “large bowel” or “large intestine”). Key symptoms include For personal use only abdominal pain or discomfort, bloating, and chronic diarrhoea or constipation, or alternating between the two. Inflam
Anatara Lifesciences — Investor Presentation (May 2023) on 6ix